KBC Group NV lowered its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 22.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 168,253 shares of the medical research company’s stock after selling 49,098 shares during the period. KBC Group NV’s holdings in Thermo Fisher Scientific were worth $25,844,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Independent Portfolio Consultants Inc. raised its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the last quarter. Advantage Investment Management LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $125,000. Ancora Advisors LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $176,000. Penserra Capital Management LLC raised its stake in Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock valued at $176,000 after buying an additional 100 shares during the last quarter. Finally, South Texas Money Management Ltd. purchased a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $202,000. Institutional investors and hedge funds own 87.15% of the company’s stock.

Thermo Fisher Scientific Inc (NYSE:TMO) traded down 1.89% on Tuesday, reaching $173.99. 1,648,460 shares of the company traded hands. The company has a market capitalization of $67.86 billion, a P/E ratio of 30.31 and a beta of 1.06. The company has a 50-day moving average price of $177.02 and a 200-day moving average price of $164.40. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The firm had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. Thermo Fisher Scientific’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.03 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 10.45%.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/08/kbc-group-nv-has-25-84-million-position-in-thermo-fisher-scientific-inc-nysetmo-updated-updated-updated.html.

Several research firms have recently commented on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a research report on Tuesday, August 1st. BidaskClub lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Bank of America Corporation reissued a “buy” rating and issued a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Finally, Barclays PLC reissued an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 17th. One equities research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $188.56.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 20,000 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the sale, the chief executive officer now directly owns 269,279 shares in the company, valued at approximately $46,528,718.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the sale, the chief financial officer now owns 37,790 shares in the company, valued at $6,660,865.40. The disclosure for this sale can be found here. Insiders have sold a total of 27,188 shares of company stock valued at $4,702,223 over the last three months. 0.49% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.